#fast track

Janssen has entered into a collaboration with Achillion to develop and commercialize hepatitis C treatments.

FDA has granted fast-track status to Galmed Pharmaceuticals’ aramchol, an investigatory treatment for non-alcoholic steatohepatitis (NASH).

The FDA has sped up the development and approval process for promising new hepatitis C therapies from three different companies.

ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...

The US Food and Drug Administration (FDA) has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625, a drug being...